唐氏综合征的肝脏新陈代谢改变
bioRxiv : the preprint server for biology
|June 12, 2025
概括
唐氏综合征 (Trisomy 21) 与显著的代谢变化有关,特别是胆酸水平和肝功能. 饮食脂肪调节显示出对患有唐氏综合征的个体影响这些变化的潜力.
科学领域:
- 遗传学和基因组学 在
- 代谢学 代谢学 代谢学
- 人类健康 人类健康 人类健康
背景情况:
- 唐氏综合症 (DS),由三胞体21 (T21) 引起,是最常见的染色体异常.
- 患有DS的个体有先天性心脏缺陷,自身免疫和阿尔茨海默病的风险增加.
- DS影响多个器官系统,表明广泛的生理影响.
研究的目的:
- 通过使用多组体分析,研究唐氏综合征患者的代谢变化.
- 为了探索Trisomy 21对胆酸代谢和肝功能的影响.
- 在唐氏综合征小鼠模型中检查食脂肪调节对肝脏新陈代谢的影响.
主要方法:
- 来自400多名唐氏综合征患者血的多原子分析.
- 使用唐氏综合症小鼠模型 (DP16) 进行机械学研究.
- 采用大量RNA测序和单细胞转录的肝脏组织.
- 研究了饮食脂肪调节对基因表达和代谢概况的影响.
主要成果:
- 在唐氏综合征患者中观察到广泛的代谢变化,包括胆酸水平升高.
- 在患有DS的个体中,鉴定出表明肝功能障碍的蛋白质特征.
- 在DS小鼠模型中证实了胆酸代谢和肝脏病理学的保留扰动.
- 揭示了Trisomy 21对肝脏新陈代谢和炎症的广泛影响,确定了特定的细胞类型.
结论:
- 唐氏综合征与肝脏代谢发生显著变化有关,其特征是胆酸通路失调.
- 唐氏综合征的肝脏病理和代谢障碍在小鼠模型中得到保护.
- 在唐氏综合征的情况下,饮食中的脂肪摄入量可以影响基因表达,胆酸概况和肝脏健康.
- 这些发现表明,饮食代表了管理唐氏综合征代谢并发症的潜在治疗途径.
相关概念视频
Inborn Errors of Metabolism
241
Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
241
Factors Affecting Drug Biotransformation: Biological
235
Biological factors significantly impact drug metabolism, influencing drug clearance, efficacy, and potential toxicity.
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
235
Overview of Carbohydrate Metabolism
1.8K
Carbohydrate metabolism is a fundamental biochemical process that ensures a constant supply of energy to living cells. The most important carbohydrate is glucose, which can be broken down via glycolysis to enter into the Krebs cycle and eventually lead to the production of ATP through oxidative phosphorylation.
Glucose transport into cells is facilitated by a family of transport proteins called GLUT (Glucose Transporters). GLUT4 is the primary glucose transporter for insulin-stimulated glucose...
Glucose transport into cells is facilitated by a family of transport proteins called GLUT (Glucose Transporters). GLUT4 is the primary glucose transporter for insulin-stimulated glucose...
1.8K
Glucose Transporters
24.1K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
24.1K
Drug Metabolism: Phase II Reactions
4.1K
Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...
4.1K
Factors Affecting Drug Response: Overview
2.4K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
2.4K


